Trial Profile
Open Label, Randomized, Multicenter Phase II Study of a Combination of Torisel (Temsirolimus) and Avastin (Bevacizumab) Versus Sutent (Sunitinib) and Versus a Combination of Avastin (Bevacizumab) and Roferon (Interferon [IFN] Alpha-2a) in First-Line Treatment of Patients With Metastatic Renal Cell Carcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Temsirolimus (Primary) ; Interferon alpha-2a; Sunitinib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms TORAVA
- 22 Mar 2018 Results assessing effect of angiogenic treatment on VE cadherin post translational modifications using patient data from SUVEGIL and TORAVA trials published in the British Journal of Cancer
- 29 Aug 2017 Results (n=99) of SUVEGIL and TORAVA trials ,published in the British Journal of Cancer.
- 15 Sep 2015 Results (metabolomic fingerprint analysis) published in the British Journal of Cancer.